Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15612976 | 0.85 | MEN1 (0.61) | MEN1KMT2AALDH1A1MAPTNPC1 | |
| SCHEMBL13532171 | 0.83 | MEN1 (0.77) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL1001379 | 0.83 | MEN1 (0.66) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL13532178 | 0.82 | KMT2A (0.69) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15705229 | 0.82 | KMT2A (0.69) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1000538 | 0.81 | MEN1 (0.68) | MEN1KMT2AALDH1A1MAPTNPC1 | |
| SCHEMBL30926445 | 0.81 | MEN1 (0.82) | MEN1KMT2AALDH1A1MAPTRAB9A | |
| SCHEMBL30926720 | 0.81 | MEN1 (0.67) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL13532193 | 0.81 | MEN1 (0.74) | MEN1KMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL27181006 | 0.81 | MEN1 (0.67) | MEN1KMT2AALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113321632-A | Sulfamoyl-arylamides and their use as medicaments for the treatment of hepatitis B | 爱尔兰詹森科学公司 | 2021-08-31 | — | — | CN | claimed |
| WO-2020255013-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND CAPSID ASSEMBLY MODULATORS BEING AMIDE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | claimed |
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | claimed |
| CN-105209031-A | Novel antiviral agents against HBV infection | UNIV DREXEL | 2015-12-30 | — | — | CN | claimed |
| EP-2938338-A2 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | Drexel University (US) | 2015-11-04 | — | — | EP | claimed |
| WO-2014106019-A2 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A DREXEL (US) | 2014-07-03 | — | — | WO | claimed |
| WO-2020255013-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND CAPSID ASSEMBLY MODULATORS BEING AMIDE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| US-9938236-B2 | Antiviral agents against HBV infection | DREXEL UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| CN-104352492-B | Extend enzyme inhibitor using arylsulfonyl derivatives as the long chain fatty acids of active ingredient | MSD K.K.公司 | 2017-12-05 | — | — | CN | disclosed |
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| CN-105209031-A | Novel antiviral agents against HBV infection | UNIV DREXEL | 2015-12-30 | — | — | CN | disclosed |
| EP-2938338-A2 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | Drexel University (US) | 2015-11-04 | — | — | EP | disclosed |
| CN-104352492-A | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | MSD KK | 2015-02-18 | — | — | CN | disclosed |
| EP-2280001-B1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD KK (JP) | 2014-10-15 | — | — | EP | disclosed |
| WO-2014106019-A2 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A DREXEL (US) | 2014-07-03 | — | — | WO | disclosed |
| US-8420823-B2 | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | MSD K.K. (JP) | 2013-04-16 | — | — | US | disclosed |
| EP-2280001-A1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-02-02 | — | — | EP | disclosed |
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD K.K. (JP) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | ELOVL1, ELOVL6, ELOVL3 | MEN1 4600/4885KMT2A 473/4885ALDH1A1 188/4885 |
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | HAVCR2, EIF2AK2, NR1H4 | MEN1 4674/4885KMT2A 3874/4885ALDH1A1 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.